These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27903791)

  • 21. Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism.
    Baldetti L; Melillo F; Beneduce A; Camici PG
    Eur Heart J Cardiovasc Imaging; 2019 Feb; 20(2):243. PubMed ID: 30535006
    [No Abstract]   [Full Text] [Related]  

  • 22. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
    Khunger M; Velcheti V
    J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
    [No Abstract]   [Full Text] [Related]  

  • 23. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
    Ansorge C; Seufert J; Meiss F; von Bubnoff D
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
    [No Abstract]   [Full Text] [Related]  

  • 24. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
    [No Abstract]   [Full Text] [Related]  

  • 25. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.
    Naito T; Osaki M; Ubano M; Kanzaki M; Uesaka Y
    Neurol Sci; 2018 Oct; 39(10):1791-1793. PubMed ID: 29948463
    [No Abstract]   [Full Text] [Related]  

  • 27. Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
    Kazandjian D; Khozin S; Blumenthal G; Zhang L; Tang S; Libeg M; Kluetz P; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):118-22. PubMed ID: 26470053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Course of Preexisting Uveitis during Treatment of Lung Cancer with Durvalumab.
    Ahmad TR; Doan T; Gonzales JA; Acharya NR; Tsui E
    Ocul Immunol Inflamm; 2020 May; 28(4):566-570. PubMed ID: 31710511
    [No Abstract]   [Full Text] [Related]  

  • 29. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab.
    Otsubo K; Nakatomi K; Furukawa R; Ashida K; Yoneshima Y; Nakanishi Y; Okamoto I
    Ann Oncol; 2017 Dec; 28(12):3106-3107. PubMed ID: 28945828
    [No Abstract]   [Full Text] [Related]  

  • 30. Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab.
    Hu J; Li Y; Chen X; Luo C; Zuo X
    J Clin Pharm Ther; 2020 Dec; 45(6):1474-1477. PubMed ID: 32662522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous appearance of intracardiac masses following chemotherapy in a patient with lung cancer.
    Shimbo M; Watanabe H; Sato K; Yamamoto H; Ito H
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):119. PubMed ID: 28950362
    [No Abstract]   [Full Text] [Related]  

  • 32. Transient thyrotoxicosis during nivolumab treatment.
    van Kooten MJ; van den Berg G; Glaudemans AWJM; Hiltermann TJN; Groen HJM; Rutgers A; Links TP
    Neth J Med; 2017 Jun; 75(5):204-207. PubMed ID: 28653941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Gion M; Remon J; Caramella C; Soria JC; Besse B
    Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
    Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
    [No Abstract]   [Full Text] [Related]  

  • 35. An 80-year-old man with idiopathic pulmonary fibrosis and new bilateral lung densities.
    Jover J; Aranda C
    Chest; 1998 Oct; 114(4):1210-2. PubMed ID: 9792598
    [No Abstract]   [Full Text] [Related]  

  • 36. Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
    Blackmon JT; Dhawan R; Terry NL; Conry RM
    Melanoma Res; 2017 Apr; 27(2):159-163. PubMed ID: 28252478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
    Chang E; Sabichi AL; Sada YH
    J Immunother; 2017 Apr; 40(3):114-116. PubMed ID: 28234667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Hall CJ; Umeweni N; Knight H; Smith L
    Lancet Oncol; 2016 Oct; 17(10):1357-1358. PubMed ID: 27567055
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature.
    Chauhan A; Burkeen G; Houranieh J; Arnold S; Anthony L
    Ann Oncol; 2017 Aug; 28(8):2034-2038. PubMed ID: 28472223
    [No Abstract]   [Full Text] [Related]  

  • 40. Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.
    Jin Y; Jiang Q; Xin T
    Thorac Cancer; 2018 Jan; 9(1):164-166. PubMed ID: 29027754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.